Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations

Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations

Randomized controlled trials (RCT) are the driver of therapeutic innovations. However, it has been frequently shown that less than 5% of adult cancer patients enroll in clinical trials, although 70% of patients are considered as being willing to participate. Barriers to trial participation have been...

Full description

Bibliographic Details
Main Authors: Amelie Boquoi, Veronika Rings, Annemarie Mohring, Ingrida Savickaite, Romans Zukovs, Judith Strapatsas, Kathrin Nachtkamp, Guido Kobbe, Ulrich Germing, Roland Fenk
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
multiple myeloma
randomized clinical trials
eligibility
real-world
Online Access:https://www.mdpi.com/2072-6694/14/9/2147

Internet

https://www.mdpi.com/2072-6694/14/9/2147

Similar Items